Nubar P Boghossian, MD
Hematology/Oncology · Glendale
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 21 years
- Graduated 2005
Offices
1 location · Los Angeles Hematology-Oncology Medical Group · 51 clinicians in this group
Hospitals listed: Glendale Adventist Medical Center · Glendale Mem Hospital & Hlth Center · Valley Presbyterian Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Boghossian’s office at (818) 553-8160 to ask if they take your plan before you enroll.
California Medical Board record
Licence A88517 · Current
Licensed to practise in California · since 2004 · expires 2028-07-31 · University of Baghdad College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Hematology
- American Board of Internal Medicine - Medical Oncology
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Glendale Adventist Medical CenterGlendale, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Adventist Health, which runs 28 hospitals in 3 statesPatients rate it 3 of 5 · 69% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Pressure ulcer rate: 0.08 (0 to 0.57) · 9,330 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.073, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.277, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.085, Oct 2024 – Sep 2025
- Glendale Mem Hospital & Hlth CenterGlendale, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.105, Oct 2024 – Sep 2025
- Valley Presbyterian HospitalVan Nuys, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPatients rate it 2 of 5 · 60% would definitely recommend itOverall rating: 1 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.049, Oct 2024 – Sep 2025
See every measure and the patient survey for Glendale Adventist Medical Center
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 4 the same, 0 worse of 7 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Pressure ulcer rateComplications and deaths | 0.08 (0 to 0.57) · 9,330 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.073 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.277 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.085 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.9 (0.01 to 1.79) · 1,817 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.75 (0.48 to 1.01) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 161.81 (119.07 to 204.55) · 188 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.1 · 70 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7 · 142 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11 · 312 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.7 · 787 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.9 · 1,340 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 352 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,776 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 11,108 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.18 (0 to 0.35) · 11,736 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3 (1.22 to 4.78) · 2,564 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.76 (0.19 to 3.33) · 882 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.38 (0.04 to 2.71) · 2,540 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.3 (2.34 to 14.26) · 947 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.26 (1.99 to 8.53) · 895 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.94 (0.47 to 3.41) · 431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.7 · 112 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.686 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.978 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.234 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.7 · 368 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.2 · 930 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 30.6 · 370 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -4.5 · 1,036 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 30.9 · 1,549 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.9 · 1,397 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (3.3 to 8.5) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.9 (7.5 to 15.5) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.9 · 105 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.4 · 68 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 171 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.8 to 17.5) · 183 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.4) · 416 cases | No different | Jan 2024 – Dec 2024 |
What patients said (759 patients answered, 15% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 81% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 51% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Glendale Mem Hospital & Hlth Center
Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 6 the same, 1 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.105 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.94 (0 to 1.97) · 609 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.49 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 154.55 (98.55 to 210.56) · 42 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 26 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 75 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.1 · 140 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.9 · 325 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.6 · 373 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.5 · 166 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,586 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 3,962 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.07 to 0.47) · 4,083 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.07 (0.76 to 5.38) · 734 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.6 (0 to 3.29) · 196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.98 (0.38 to 3.58) · 750 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.99 (0.29 to 17.7) · 201 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.34 (2.25 to 10.43) · 187 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.72 (0.21 to 3.23) · 126 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.2 (0 to 0.95) · 3,409 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.7 · 205 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.349 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.343 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.42 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.269 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 155 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 404 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -15.2 · 151 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.2 · 421 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 34.6 · 433 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.4 · 368 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.4 · 182 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 42 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.5 · 99 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.5 to 16.5) · 613 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.4) · 158 cases | No different | Jan 2024 – Dec 2024 |
What patients said (565 patients answered, 10% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 80% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Valley Presbyterian Hospital
Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 6 the same, 2 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.049 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.97 (0 to 2.02) · 594 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.48 to 1.25) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 156.9 (96.19 to 217.61) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 53 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 79 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 216 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.4 · 325 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 15.1 · 70 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.4 · 1,116 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.23 (0.02 to 0.45) · 3,518 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 3,606 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.27 (0.88 to 5.65) · 646 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 217 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.04 (0.42 to 3.66) · 635 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.41 (0 to 16.47) · 226 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.87 (0.68 to 9.06) · 208 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.73 (0.21 to 3.25) · 125 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.46 (0 to 1.24) · 3,088 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 89 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.574 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.06 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.874 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.935 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 84 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.7 · 271 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 83.7 · 85 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 59.4 · 264 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 17.7 · 360 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.5 · 359 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 91 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 72 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.6 (9.2 to 17) · 88 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 56 cases | No different | Jan 2024 – Dec 2024 |
What patients said (397 patients answered, 13% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 1 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 2 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 70% |
| Doctors "always" communicated well | 66% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 81% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 61% |
| Doctors "always" listened carefully | 66% |
| Doctors "always" treated them with courtesy and respect | 72% |
| Patients who gave a rating of "9" or "10" (high) | 62% |
| Staff "always" explained new medications | 66% |
| Nurses "always" explained things so they could understand | 65% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 76% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 60% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 82% |
Original Medicare doctor bills
$1,470,870
Medicare paid this office $1,470,870 for 507 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, denosumab, 1 mg | 46 | $119,953 | None |
| Return visit (30+ min) | 363 | $97,253 | $100 |
| Short return visit (20+ min) | 286 | $39,448 | $70 |
| Administration of chemotherapy into vein, 1 hour or less | 31 | $21,175 | $112 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 35 | $10,570 | $54 |
See all 26 services
| Injection, denosumab, 1 mg | 46 | $119,953 | None |
| Return visit (30+ min) | 363 | $97,253 | $100 |
| Short return visit (20+ min) | 286 | $39,448 | $70 |
| Administration of chemotherapy into vein, 1 hour or less | 31 | $21,175 | $112 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 35 | $10,570 | $54 |
| New patient visit (60+ min) | 63 | $10,360 | $164 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $7,192 | $97 |
| Injection of drug or substance under skin or into muscle | 109 | $6,946 | $12 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 13 | $4,901 | $18 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 47 | $4,758 | $24 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $3,889 | $139 |
| Administration of additional new drug or substance into vein, 1 hour or less | 15 | $3,528 | $56 |
| Insertion of needle into vein for collection of blood sample | 129 | $2,988 | $9 |
| Drawing of blood for a medical problem | 12 | $2,829 | $71 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $2,106 | $31 |
| Long return visit (40+ min) | 12 | $1,792 | $149 |
| Assessment of emotional or behavioral problems | 288 | $1,476 | $3 |
| Infusion into a vein for hydration, 31-60 minutes | 15 | $1,396 | $29 |
| Administration of chemotherapy into vein, each additional hour | 13 | $1,335 | $23 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 32 | $900 | $8 |
| Injection, palonosetron hcl, 25 mcg | 12 | $266 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 42 | $256 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 48 | $234 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 17 | $188 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 45 | $95 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 11 | $58 | None |
Who their Medicare patients are
507 Original Medicare patients in 2024. Average age 73 · Under 65 11% · 85 and older 11% · Women 70% · Also on Medicaid 85% · Health risk score 1.77. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 75% · Diabetes 55% · Cancer 55% · Coronary heart disease 39% · Depression 32% · Chronic kidney disease 30% · Heart failure 24% · COPD 20% · Dementia 16% · Atrial fibrillation 15% · Stroke 11%.
The office billed $5,479,792, Medicare allowed $1,869,538 and paid $1,470,870; for 73,426 services of 87 kinds; $1,237,083 of it was for drugs given in the office and $233,787 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 507 | 73,426 | 73 | 1.77 | $5,479,792 | $1,470,870 |
| 2023 | 483 | 58,819 | 73 | 1.78 | $2,891,122 | $740,965 |
| 2022 | 438 | 42,324 | 73 | 1.88 | $1,172,145 | $339,884 |
| 2021 | 379 | 39,007 | 72 | 1.67 | $1,563,774 | $637,360 |
| 2020 | 344 | 64,355 | 72 | 1.77 | $2,187,960 | $864,171 |
| 2019 | 337 | 64,705 | 73 | 2.08 | $1,372,374 | $566,998 |
| 2018 | 343 | 129,685 | 74 | 2.10 | $2,192,610 | $904,127 |
| 2017 | 326 | 159,083 | 74 | 1.86 | $2,229,600 | $894,693 |
| 2016 | 339 | 96,631 | 74 | 1.98 | $1,464,304 | $567,970 |
| 2015 | 323 | 93,406 | 75 | 2.14 | $1,631,331 | $630,297 |
| 2014 | 373 | 115,653 | 75 | 2.14 | $2,089,366 | $818,232 |
| 2013 | 469 | 59,496 | 75 | 2.46 | $1,691,779 | $608,399 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 27 services
| Return visit (30+ min) | 311 | $96,386 | $102 |
| Short return visit (20+ min) | 248 | $33,312 | $67 |
| Administration of chemotherapy into vein, 1 hour or less | 30 | $24,055 | $117 |
| Injection, denosumab, 1 mg | 25 | $20,231 | None |
| New patient visit (60+ min) | 70 | $12,017 | $172 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 66 | $10,242 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $9,174 | $99 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 17 | $6,832 | $0 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 70 | $6,219 | $25 |
| Administration of additional new drug or substance into vein, 1 hour or less | 12 | $4,170 | $58 |
| Injection of drug or substance under skin or into muscle | 72 | $4,140 | $11 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $3,487 | $145 |
| Insertion of needle into vein for collection of blood sample | 123 | $2,579 | $8 |
| Long return visit (40+ min) | 12 | $1,843 | $154 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 28 | $1,197 | $18 |
| Assessment of emotional or behavioral problems | 219 | $1,184 | $4 |
| Infusion into a vein for hydration, 31-60 minutes | 12 | $923 | $30 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 45 | $829 | $8 |
| Injection, palonosetron hcl, 25 mcg | 13 | $360 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 32 | $244 | None |
| Injection, zoledronic acid, 1 mg | 17 | $240 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 67 | $197 | None |
| Blood test, comprehensive group of blood chemicals | 19 | $197 | $10 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 22 | $129 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 61 | $90 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 18 | $90 | None |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 20 | $0 | None |
2022: 24 services
| Return visit (30+ min) | 256 | $67,437 | $109 |
| Short return visit (20+ min) | 282 | $34,859 | $62 |
| Administration of chemotherapy into vein, 1 hour or less | 21 | $23,913 | $124 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 21 | $15,646 | $1 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 53 | $12,590 | $159 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 59 | $10,923 | $60 |
| New patient visit (60+ min) | 57 | $8,525 | $150 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 61 | $7,561 | $26 |
| Long return visit (40+ min) | 43 | $6,981 | $155 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $6,857 | $87 |
| Injection, denosumab, 1 mg | 14 | $6,118 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $5,521 | $167 |
| Injection of drug or substance under skin or into muscle | 53 | $2,703 | $12 |
| Insertion of needle into vein for collection of blood sample | 138 | $1,062 | $3 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 54 | $830 | $8 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 21 | $790 | $17 |
| Infusion into a vein for hydration, 31-60 minutes | 14 | $726 | $32 |
| Injection, palonosetron hcl, 25 mcg | 16 | $193 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 28 | $178 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 60 | $172 | None |
| Injection, zoledronic acid, 1 mg | 12 | $128 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 17 | $122 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 55 | $99 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 17 | $91 | None |
2021: 24 services
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 98 | $71,739 | $160 |
| Short return visit (20+ min) | 310 | $65,596 | $70 |
| Return visit (30+ min) | 48 | $30,570 | $113 |
| Administration of chemotherapy into vein, 1 hour or less | 26 | $25,728 | $133 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 42 | $10,784 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 41 | $10,023 | $89 |
| New patient visit (60+ min) | 49 | $8,443 | $172 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 35 | $8,317 | $28 |
| Administration of additional new drug or substance into vein, 1 hour or less | 12 | $5,180 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,414 | $170 |
| Injection of drug or substance under skin or into muscle | 46 | $2,660 | $12 |
| Administration of chemotherapy into vein, each additional hour | 11 | $2,023 | $28 |
| Injection, zoledronic acid, 1 mg | 16 | $1,172 | None |
| Injection, palonosetron hcl, 25 mcg | 16 | $1,162 | None |
| Insertion of needle into vein for collection of blood sample | 122 | $1,092 | $3 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 49 | $1,026 | $8 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 11 | $935 | $20 |
| Infusion into a vein for hydration, 31-60 minutes | 13 | $868 | $31 |
| Injection, dexamethasone sodium phosphate, 1 mg | 35 | $239 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 20 | $160 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 21 | $134 | None |
| Injection, magnesium sulfate, per 500 mg | 18 | $78 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 31 | $73 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 20 | $59 | None |
2020: 23 services
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 80 | $73,404 | $159 |
| Short return visit (20+ min) | 285 | $50,123 | $58 |
| Administration of chemotherapy into vein, 1 hour or less | 21 | $19,979 | $132 |
| Return visit (30+ min) | 31 | $19,402 | $95 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 44 | $10,006 | $61 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 11 | $8,590 | $1 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 44 | $8,470 | $28 |
| New patient visit (60+ min) | 40 | $6,676 | $167 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $4,859 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $4,141 | $173 |
| Injection, palonosetron hcl, 25 mcg | 13 | $1,979 | None |
| Injection of drug or substance under skin or into muscle | 35 | $1,630 | $11 |
| Injection, zoledronic acid, 1 mg | 13 | $1,619 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 35 | $980 | $8 |
| Insertion of needle into vein for collection of blood sample | 111 | $961 | $3 |
| Injection of additional new drug or substance into vein | 11 | $703 | $15 |
| Injection, dexamethasone sodium phosphate, 1 mg | 42 | $296 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 40 | $111 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 17 | $107 | None |
| Injection, magnesium sulfate, per 500 mg | 17 | $97 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 18 | $96 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 16 | $82 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 14 | $53 | None |
2019: 23 services
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 91 | $77,616 | $157 |
| Short return visit (20+ min) | 266 | $47,223 | $58 |
| Administration of chemotherapy into vein, 1 hour or less | 24 | $20,681 | $128 |
| Return visit (30+ min) | 41 | $17,531 | $90 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 47 | $14,026 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $12,656 | $87 |
| New patient visit (60+ min) | 59 | $9,624 | $163 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 47 | $8,433 | $27 |
| Injection, palonosetron hcl, 25 mcg | 12 | $5,831 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $3,996 | $160 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 84 | $2,284 | $8 |
| Injection of drug or substance under skin or into muscle | 41 | $2,230 | $14 |
| Injection of additional new drug or substance into vein | 27 | $1,436 | $15 |
| Insertion of needle into vein for collection of blood sample | 119 | $1,114 | $3 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 12 | $429 | $19 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 19 | $371 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 44 | $363 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 18 | $272 | None |
| Injection, magnesium sulfate, per 500 mg | 23 | $169 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 18 | $148 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 42 | $130 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 20 | $89 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 17 | $46 | None |
2018: 26 services
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 80 | $76,205 | $157 |
| Return visit (30+ min) | 117 | $39,352 | $83 |
| Short return visit (20+ min) | 240 | $39,206 | $60 |
| Injection, ferric carboxymaltose, 1 mg | 22 | $28,451 | None |
| Administration of chemotherapy into vein, 1 hour or less | 34 | $28,098 | $126 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 19 | $19,523 | $1 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 63 | $18,887 | $64 |
| Injection, palonosetron hcl, 25 mcg | 19 | $15,748 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 48 | $13,160 | $87 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 63 | $11,733 | $28 |
| Administration of additional new drug or substance into vein, 1 hour or less | 17 | $9,617 | $62 |
| New patient visit (60+ min) | 58 | $9,145 | $158 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $5,785 | $161 |
| Injection of drug or substance under skin or into muscle | 59 | $5,190 | $17 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 109 | $3,450 | $9 |
| Injection of additional new drug or substance into vein | 46 | $2,563 | $16 |
| Insertion of needle into vein for collection of blood sample | 134 | $1,297 | $3 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 17 | $752 | $20 |
| Injection, dexamethasone sodium phosphate, 1 mg | 60 | $488 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 21 | $475 | None |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 29 | $248 | None |
| Injection, magnesium sulfate, per 500 mg | 32 | $230 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 26 | $135 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 28 | $131 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 57 | $123 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 16 | $40 | None |
2017: 27 services
| Return visit (30+ min) | 192 | $73,826 | $90 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 69 | $65,072 | $157 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 20 | $41,650 | $1 |
| Injection, ferric carboxymaltose, 1 mg | 23 | $27,457 | None |
| Administration of chemotherapy into vein, 1 hour or less | 24 | $25,618 | $125 |
| Injection, palonosetron hcl, 25 mcg | 18 | $20,471 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 56 | $17,767 | $62 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 55 | $11,711 | $27 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $10,873 | $88 |
| Injection of drug or substance under skin or into muscle | 47 | $9,640 | $22 |
| New patient visit (60+ min) | 51 | $8,513 | $167 |
| Short return visit (20+ min) | 126 | $7,997 | $47 |
| Administration of additional new drug or substance into vein, 1 hour or less | 12 | $7,542 | $59 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $6,717 | $172 |
| Injection of additional new drug or substance into vein | 39 | $4,250 | $20 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 101 | $4,055 | $10 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 25 | $1,705 | $16 |
| Administration of chemotherapy into vein, each additional hour | 12 | $1,680 | $25 |
| Insertion of needle into vein for collection of blood sample | 107 | $1,173 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 50 | $514 | None |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 26 | $223 | None |
| Injection, magnesium sulfate, per 500 mg | 24 | $194 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 17 | $191 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 52 | $149 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 17 | $137 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 17 | $117 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 16 | $34 | None |
2016: 26 services
| Return visit (30+ min) | 82 | $29,432 | $90 |
| Short return visit (20+ min) | 231 | $27,736 | $56 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 41 | $26,186 | $157 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 15 | $23,785 | $1 |
| Injection, palonosetron hcl, 25 mcg | 19 | $21,204 | None |
| Administration of chemotherapy into vein, 1 hour or less | 23 | $20,247 | $123 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 48 | $13,394 | $60 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 45 | $8,992 | $27 |
| New patient visit (60+ min) | 51 | $8,413 | $165 |
| Injection of drug or substance under skin or into muscle | 37 | $6,249 | $22 |
| Administration of additional new drug or substance into vein, 1 hour or less | 14 | $5,866 | $56 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $5,726 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 31 | $5,278 | $170 |
| Injection of additional new drug or substance into vein | 28 | $3,867 | $20 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 26 | $3,060 | $16 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 96 | $2,408 | $10 |
| Administration of chemotherapy into vein, each additional hour | 11 | $1,342 | $25 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 24 | $912 | None |
| Insertion of needle into vein for collection of blood sample | 114 | $826 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 44 | $420 | None |
| Injection, ranitidine hydrochloride, 25 mg | 29 | $195 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 43 | $99 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 16 | $98 | None |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 13 | $84 | None |
| Injection, magnesium sulfate, per 500 mg | 22 | $67 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 14 | $47 | None |
2015: 29 services
| Injection, sargramostim (gm-csf), 50 mcg | 21 | $88,633 | None |
| Short return visit (20+ min) | 223 | $31,972 | $56 |
| Return visit (30+ min) | 68 | $31,473 | $91 |
| Administration of chemotherapy into vein, 1 hour or less | 32 | $24,459 | $120 |
| Injection, palonosetron hcl, 25 mcg | 24 | $23,251 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 48 | $16,154 | $62 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 53 | $11,779 | $26 |
| Injection of drug or substance under skin or into muscle | 44 | $10,759 | $22 |
| Administration of additional new drug or substance into vein, 1 hour or less | 14 | $8,129 | $56 |
| Injection, zoledronic acid, 1 mg | 14 | $7,116 | None |
| New patient visit (60+ min) | 39 | $6,351 | $163 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $5,815 | $166 |
| Injection of additional new drug or substance into vein | 38 | $4,669 | $19 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $4,513 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 31 | $4,077 | $57 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 30 | $3,196 | $16 |
| Administration of chemotherapy into vein, each additional hour | 15 | $1,962 | $25 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 37 | $1,880 | None |
| Return visit (30+ min) | 12 | $1,123 | $66 |
| Injection of drug or substance into vein | 13 | $763 | $40 |
| Injection, dexamethasone sodium phosphate, 1 mg | 49 | $613 | None |
| Insertion of needle into vein for collection of blood sample | 91 | $426 | $3 |
| Injection, ranitidine hydrochloride, 25 mg | 41 | $311 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 48 | $131 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 17 | $115 | None |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 12 | $88 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 12 | $84 | None |
| Injection, magnesium sulfate, per 500 mg | 29 | $74 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 23 | $67 | None |
2014: 30 services
| Injection, sargramostim (gm-csf), 50 mcg | 23 | $63,402 | None |
| Short return visit (20+ min) | 247 | $42,321 | $57 |
| Return visit (30+ min) | 86 | $41,908 | $90 |
| Administration of chemotherapy into vein, 1 hour or less | 40 | $34,279 | $117 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 72 | $20,701 | $59 |
| Injection, zoledronic acid, 1 mg | 19 | $18,164 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 77 | $16,209 | $26 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 13 | $16,023 | None |
| Injection, palonosetron hcl, 25 mcg | 16 | $15,584 | None |
| Injection of drug or substance under skin or into muscle | 70 | $13,948 | $21 |
| New patient visit (60+ min) | 55 | $9,323 | $170 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 53 | $9,006 | $167 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 73 | $8,986 | $60 |
| Injection of additional new drug or substance into vein | 48 | $7,267 | $19 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $6,027 | $85 |
| Administration of additional new drug or substance into vein, 1 hour or less | 17 | $4,752 | $55 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 40 | $4,217 | $16 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 38 | $3,000 | None |
| Injection of drug or substance into vein | 23 | $2,329 | $48 |
| Administration of chemotherapy into vein, each additional hour | 15 | $1,676 | $25 |
| Infusion into a vein for hydration, each additional hour | 12 | $756 | $13 |
| Injection, dexamethasone sodium phosphate, 1 mg | 75 | $713 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 13 | $293 | $17 |
| Injection, ondansetron hydrochloride, per 1 mg | 31 | $260 | None |
| Injection, ranitidine hydrochloride, 25 mg | 47 | $248 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 72 | $183 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 29 | $139 | None |
| Injection, magnesium sulfate, per 500 mg | 38 | $105 | None |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 20 | $96 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 28 | $50 | None |
2013: 31 services
| Return visit (30+ min) | 108 | $44,963 | $91 |
| Injection, sargramostim (gm-csf), 50 mcg | 24 | $42,833 | None |
| Short return visit (20+ min) | 252 | $42,179 | $57 |
| Administration of chemotherapy into vein, 1 hour or less | 38 | $28,061 | $126 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 80 | $28,053 | $65 |
| Injection, docetaxel, 1 mg | 11 | $21,584 | None |
| Zoldedronic acid 1mg | 11 | $19,727 | $136 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 89 | $17,449 | $27 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 86 | $13,721 | $160 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 125 | $12,915 | $58 |
| Injection of drug or substance under skin or into muscle | 85 | $11,483 | $22 |
| New patient visit (60+ min) | 68 | $11,246 | $165 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 11 | $10,672 | None |
| Injection, palonosetron hcl, 25 mcg | 14 | $8,777 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 15 | $7,103 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 43 | $6,040 | $83 |
| Injection of additional new drug or substance into vein | 57 | $5,641 | $19 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 53 | $5,505 | $19 |
| Administration of chemotherapy into vein, each additional hour | 17 | $3,662 | $27 |
| Injection of drug or substance into vein | 22 | $2,407 | $50 |
| Injection, iron dextran, 50 mg | 31 | $2,363 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 29 | $1,821 | None |
| Long return visit (40+ min) | 12 | $1,336 | $111 |
| Injection, dexamethasone sodium phosphate, 1 mg | 85 | $614 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 29 | $316 | None |
| Infusion into a vein for hydration, each additional hour | 12 | $270 | $13 |
| Injection, diphenhydramine hcl, up to 50 mg | 84 | $265 | None |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 37 | $226 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 41 | $94 | None |
| Injection, magnesium sulfate, per 500 mg | 30 | $90 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 24 | $27 | None |
Medicaid work
$416,895 in 2024
Medicaid paid $416,895 for 13,697 billed services this clinician did in 2024, up to 236 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Goserelin acetate implant, per 3.6 mg | 329 | $105,570 |
| Denosumab injection | 128 | $87,476 |
| Injection, pertuzumab, 1 mg | 16 | $63,557 |
| Return visit (30+ min) | 2,592 | $49,342 |
| Short return visit (20+ min) | 1,581 | $17,168 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 704 | $12,213 |
| New patient visit (60+ min) | 321 | $11,584 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 1,349 | $11,115 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 725 | $9,927 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 416 | $9,743 |
| Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 352 | $8,949 |
| Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure) | 305 | $5,922 |
| 2024 | 13,697 | 27 | 236 | $416,895 |
| 2023 | 13,970 | 28 | 207 | $312,919 |
| 2022 | 10,257 | 23 | 247 | $262,797 |
| 2021 | 13,024 | 25 | 264 | $432,644 |
| 2020 | 12,153 | 30 | 269 | $976,702 |
| 2019 | 13,508 | 24 | 231 | $1,109,675 |
| 2018 | 14,491 | 27 | 167 | $1,105,255 |
See the largest Medicaid services in earlier years
2023
| Goserelin acetate implant, per 3.6 mg | 269 | $86,618 |
| Return visit (30+ min) | 2,780 | $73,697 |
| Short return visit (20+ min) | 1,817 | $27,655 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 872 | $23,495 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 603 | $15,340 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 1,183 | $14,772 |
| Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | 31 | $12,369 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 808 | $11,896 |
| New patient visit (60+ min) | 261 | $11,010 |
| Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 271 | $8,412 |
| Brief emotional/behavioral assessment (eg, depression inventory, attention-deficit/hyperactivity disorder [ADHD] scale), with scoring and documentation, per standardized instrument | 819 | $5,205 |
| Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure) | 244 | $5,001 |
2022
| Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | 69 | $89,171 |
| Return visit (30+ min) | 1,641 | $41,617 |
| Short return visit (20+ min) | 1,943 | $33,941 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 649 | $17,060 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 746 | $14,738 |
| New patient visit (60+ min) | 166 | $12,730 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 691 | $11,586 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 522 | $10,466 |
| Injection, dexamethasone sodium phosphate, 1 mg | 703 | $6,900 |
| Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure) | 242 | $5,283 |
| Injection, ondansetron hydrochloride, per 1 mg | 588 | $2,955 |
| Palonosetron hcl | 327 | $2,375 |
2021
| Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg | 38 | $73,110 |
| Short return visit (20+ min) | 2,927 | $63,144 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 785 | $59,525 |
| Goserelin acetate implant, per 3.6 mg | 117 | $37,943 |
| Return visit (30+ min) | 946 | $29,978 |
| Injection, dexamethasone sodium phosphate, 1 mg | 896 | $25,040 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 766 | $20,309 |
| Injection, ondansetron hydrochloride, per 1 mg | 873 | $18,297 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 342 | $14,596 |
| Injection, diphenhydramine hcl, up to 50 mg | 876 | $13,776 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 806 | $13,624 |
| New patient visit (60+ min) | 181 | $12,071 |
2020
| Injection, pertuzumab, 1 mg | 104 | $274,434 |
| Injection, trastuzumab, excludes biosimilar, 10 mg | 88 | $202,034 |
| Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | 33 | $84,892 |
| Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg | 40 | $67,166 |
| Injection, dexamethasone sodium phosphate, 1 mg | 809 | $60,522 |
| Short return visit (20+ min) | 2,555 | $52,218 |
| Return visit (30+ min) | 929 | $37,991 |
| Injection, fosaprepitant, 1 mg | 168 | $21,752 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 423 | $21,184 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 781 | $21,150 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 206 | $19,184 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 617 | $16,189 |
2019
| Injection, trastuzumab, excludes biosimilar, 10 mg | 108 | $376,361 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 591 | $99,762 |
| Palonosetron hcl | 393 | $87,524 |
| Return visit (30+ min) | 1,028 | $73,593 |
| Short return visit (20+ min) | 2,568 | $63,488 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 1,105 | $60,438 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 803 | $49,413 |
| Cyclophosphamide, 100 mg | 90 | $41,375 |
| Injection, fosaprepitant, 1 mg | 132 | $37,920 |
| Docetaxel injection | 193 | $35,778 |
| Injection, diphenhydramine hcl, up to 50 mg | 742 | $32,153 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 842 | $30,864 |
2018
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 1,484 | $267,862 |
| Injection, trastuzumab, excludes biosimilar, 10 mg | 66 | $202,274 |
| Return visit (30+ min) | 1,410 | $100,331 |
| Palonosetron hcl | 487 | $93,145 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 826 | $82,634 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 1,141 | $71,489 |
| Docetaxel injection | 273 | $57,815 |
| Short return visit (20+ min) | 1,565 | $45,067 |
| Injection, fosaprepitant, 1 mg | 156 | $41,054 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 727 | $23,242 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 1,430 | $22,867 |
| Injection, dexamethasone sodium phosphate, 1 mg | 919 | $19,068 |
Drugs they prescribed that Part D paid
$6,025,498
Pharmacies billed $6,025,498 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
1,020 generic and 719 brand-name prescriptions · $6,025,498 in drug cost · 26 antibiotic prescriptions to 16 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Verzenio | 43 | $601,384 | $13,986 |
| Imbruvica | 31 | $565,780 | $18,251 |
| Kisqali | 26 | $409,998 | $15,769 |
| Calquence | 22 | $339,975 | $15,453 |
| Pomalyst | 13 | $303,247 | $23,327 |
See all 47 drugs
| Verzenio | 43 | $601,384 | $13,986 |
| Imbruvica | 31 | $565,780 | $18,251 |
| Kisqali | 26 | $409,998 | $15,769 |
| Calquence | 22 | $339,975 | $15,453 |
| Pomalyst | 13 | $303,247 | $23,327 |
| Revlimid | 18 | $296,680 | $16,482 |
| Xtandi | 22 | $290,112 | $13,187 |
| Enhertu | 18 | $250,675 | $13,926 |
| Procrit | 74 | $233,014 | $3,149 |
| Jakafi | 14 | $228,752 | $16,339 |
| Tagrisso | 12 | $207,478 | $17,290 |
| Somatuline Depot | 23 | $194,502 | $8,457 |
| Sprycel | 11 | $190,775 | $17,343 |
| Lupron Depot | 45 | $147,016 | $3,267 |
| Mvasi | 12 | $94,325 | $7,860 |
| Xgeva | 21 | $66,228 | $3,154 |
| Abiraterone Acetate | 23 | $63,216 | $2,749 |
| Trazimera | 11 | $41,714 | $3,792 |
| Ruxience | 11 | $35,147 | $3,195 |
| Zarxio | 35 | $32,164 | $919 |
| Prolia | 20 | $31,758 | $1,588 |
| Retacrit | 36 | $31,136 | $865 |
| Eliquis | 28 | $18,733 | $669 |
| Fulvestrant | 14 | $11,099 | $793 |
| Eligard | 12 | $6,475 | $540 |
| Exemestane | 30 | $5,295 | $177 |
| Bortezomib | 12 | $3,622 | $302 |
| Letrozole | 244 | $3,047 | $12 |
| Carboplatin | 37 | $2,015 | $54 |
| Palonosetron | 60 | $2,011 | $34 |
| Gemcitabine | 14 | $1,096 | $78 |
| Irinotecan | 11 | $1,006 | $91 |
| Fosaprepitant Dimeglumine | 14 | $845 | $60 |
| Paclitaxel | 11 | $777 | $71 |
| Dexamethasone | 48 | $526 | $11 |
| Anastrozole | 51 | $400 | $8 |
| Hydroxyurea | 30 | $343 | $11 |
| Anagrelide | 14 | $306 | $22 |
| Dexamethasone Sodium Phosphate | 44 | $252 | $6 |
| Ondansetron Odt | 13 | $212 | $16 |
| Prednisone | 28 | $134 | $5 |
| Diphenhydramine | 44 | $84 | $2 |
| Ondansetron | 20 | $57 | $3 |
| Famotidine | 37 | $52 | $1 |
| Famotidine | 22 | $48 | $2 |
| Metoclopramide | 21 | $27 | $1 |
| Sertraline | 12 | $18 | $2 |
Year by year
| 2024 | 1,739 | 269 | None | 41% | $6,025,498 |
| 2023 | 1,818 | 217 | None | None | $6,505,925 |
| 2022 | 2,074 | 265 | 1% (13) | 25% | $5,149,478 |
| 2021 | 2,092 | 255 | 2% (35) | 28% | $3,956,080 |
| 2020 | 1,287 | 214 | 2% (19) | 32% | $3,182,771 |
| 2019 | 1,373 | 199 | 2% (20) | 34% | $3,494,744 |
| 2018 | 1,616 | 199 | 1% (13) | 34% | $3,458,735 |
| 2017 | 1,323 | 175 | 1% (19) | 32% | $2,442,008 |
| 2016 | 1,226 | 175 | 1% (15) | 28% | $1,861,064 |
| 2015 | 1,442 | 181 | 3% (45) | None | $1,959,805 |
| 2014 | 1,599 | 188 | 5% (78) | None | $1,925,291 |
| 2013 | 1,507 | 186 | 5% (72) | None | $1,632,709 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 41 drugs
| Verzenio | 60 | $947,864 | $15,798 |
| Revlimid | 27 | $500,558 | $18,539 |
| Calquence | 27 | $412,052 | $15,261 |
| Imbruvica | 25 | $408,809 | $16,352 |
| Mvasi | 43 | $296,823 | $6,903 |
| Enhertu | 29 | $289,409 | $9,980 |
| Jakafi | 12 | $225,845 | $18,820 |
| Procrit | 61 | $225,651 | $3,699 |
| Tagrisso | 12 | $217,821 | $18,152 |
| Afinitor | 11 | $202,896 | $18,445 |
| Erivedge | 13 | $198,495 | $15,269 |
| Abiraterone Acetate | 32 | $180,291 | $5,634 |
| Somatuline Depot | 14 | $151,251 | $10,804 |
| Sunitinib Malate | 16 | $93,343 | $5,834 |
| Lupron Depot | 27 | $70,813 | $2,623 |
| Orgovyx | 16 | $45,289 | $2,831 |
| Ruxience | 14 | $35,610 | $2,544 |
| Irinotecan | 19 | $32,919 | $1,733 |
| Prolia | 15 | $26,820 | $1,788 |
| Zarxio | 21 | $20,026 | $954 |
| Eliquis | 31 | $19,966 | $644 |
| Docetaxel | 12 | $16,607 | $1,384 |
| Exemestane | 45 | $11,784 | $262 |
| Cyclophosphamide | 15 | $9,669 | $645 |
| Zoledronic Acid | 47 | $9,138 | $194 |
| Letrozole | 241 | $6,767 | $28 |
| Palonosetron | 74 | $4,960 | $67 |
| Fosaprepitant Dimeglumine | 15 | $2,808 | $187 |
| Anastrozole | 54 | $1,640 | $30 |
| Hydroxyurea | 40 | $1,292 | $32 |
| Tamoxifen Citrate | 11 | $456 | $41 |
| Dexamethasone Sodium Phosphate | 104 | $450 | $4 |
| Atropine Sulfate | 18 | $322 | $18 |
| Diphenhydramine | 102 | $239 | $2 |
| Ondansetron Odt | 13 | $218 | $17 |
| Prednisone | 36 | $214 | $6 |
| Anagrelide | 12 | $205 | $17 |
| Warfarin | 11 | $176 | $16 |
| Famotidine | 93 | $158 | $2 |
| Ondansetron | 25 | $91 | $4 |
| Metoclopramide | 20 | $67 | $3 |
2022: 39 drugs
| Verzenio | 42 | $633,814 | $15,091 |
| Revlimid | 26 | $472,382 | $18,169 |
| Imbruvica | 31 | $470,682 | $15,183 |
| Calquence | 24 | $356,675 | $14,861 |
| Jakafi | 12 | $214,501 | $17,875 |
| Xtandi | 16 | $190,239 | $11,890 |
| Mvasi | 29 | $179,868 | $6,202 |
| Procrit | 39 | $171,148 | $4,388 |
| Nerlynx | 19 | $168,618 | $8,875 |
| Keytruda | 20 | $146,173 | $7,309 |
| Abiraterone Acetate | 25 | $119,854 | $4,794 |
| Neulasta | 16 | $110,528 | $6,908 |
| Lupron Depot | 30 | $97,498 | $3,250 |
| Enhertu | 16 | $86,903 | $5,431 |
| Lapatinib | 11 | $42,766 | $3,888 |
| Exemestane | 101 | $31,577 | $313 |
| Irinotecan | 11 | $24,306 | $2,210 |
| Prolia | 11 | $17,396 | $1,581 |
| Letrozole | 472 | $12,123 | $26 |
| Xarelto | 16 | $11,674 | $730 |
| Zoledronic Acid | 29 | $9,638 | $332 |
| Palonosetron | 71 | $7,269 | $102 |
| Oxaliplatin | 12 | $4,027 | $336 |
| Hydroxyurea | 50 | $1,497 | $30 |
| Carboplatin | 19 | $1,436 | $76 |
| Anastrozole | 87 | $1,223 | $14 |
| Tamoxifen Citrate | 21 | $705 | $34 |
| Anagrelide | 12 | $635 | $53 |
| Megestrol Acetate | 14 | $606 | $43 |
| Diphenhydramine | 96 | $398 | $4 |
| Dexamethasone Sodium Phosphate | 92 | $369 | $4 |
| Ondansetron Odt | 16 | $346 | $22 |
| Prednisone | 31 | $237 | $8 |
| Ondansetron | 62 | $199 | $3 |
| Famotidine | 85 | $177 | $2 |
| Atropine Sulfate | 11 | $174 | $16 |
| Warfarin | 13 | $104 | $8 |
| Magnesium Sulfate | 21 | $76 | $4 |
| Metoclopramide | 24 | $68 | $3 |
2021: 45 drugs
| Imbruvica | 37 | $535,969 | $14,486 |
| Verzenio | 28 | $385,565 | $13,770 |
| Revlimid | 18 | $322,912 | $17,940 |
| Inlyta | 14 | $216,336 | $15,453 |
| Keytruda | 25 | $201,049 | $8,042 |
| Mvasi | 51 | $195,822 | $3,840 |
| Jakafi | 12 | $194,282 | $16,190 |
| Procrit | 32 | $140,516 | $4,391 |
| Xtandi | 13 | $132,903 | $10,223 |
| Nerlynx | 12 | $116,586 | $9,715 |
| Imatinib Mesylate | 11 | $107,561 | $9,778 |
| Alimta | 18 | $83,498 | $4,639 |
| Xgeva | 24 | $63,581 | $2,649 |
| Velcade | 13 | $47,216 | $3,632 |
| Lupron Depot | 17 | $46,530 | $2,737 |
| Sancuso | 16 | $32,026 | $2,002 |
| Exemestane | 99 | $19,141 | $193 |
| Zarxio | 17 | $18,772 | $1,104 |
| Prolia | 12 | $17,165 | $1,430 |
| Letrozole | 450 | $12,922 | $29 |
| Xarelto | 16 | $10,954 | $685 |
| Zoledronic Acid | 32 | $9,197 | $287 |
| Docetaxel | 11 | $6,590 | $599 |
| Palonosetron | 37 | $5,899 | $159 |
| Irinotecan | 15 | $1,836 | $122 |
| Fosaprepitant Dimeglumine | 11 | $1,718 | $156 |
| Anastrozole | 85 | $1,639 | $19 |
| Hydroxyurea | 59 | $1,465 | $25 |
| Tamoxifen Citrate | 35 | $1,421 | $41 |
| Gemcitabine | 16 | $1,067 | $67 |
| Carboplatin | 18 | $1,001 | $56 |
| Bicalutamide | 12 | $738 | $62 |
| Dexamethasone | 27 | $474 | $18 |
| Ondansetron Odt | 12 | $281 | $23 |
| Dexamethasone Sodium Phosphate | 78 | $273 | $4 |
| Ondansetron | 69 | $222 | $3 |
| Hydrocodone-Acetaminophen | 11 | $207 | $19 |
| Famotidine | 101 | $201 | $2 |
| Metoclopramide | 56 | $195 | $3 |
| Diphenhydramine | 80 | $163 | $2 |
| Magnesium Sulfate | 50 | $144 | $3 |
| Ciprofloxacin | 13 | $81 | $6 |
| Sodium Chloride | 15 | $69 | $5 |
| Warfarin | 13 | $61 | $5 |
| Tramadol | 11 | $39 | $4 |
2020: 28 drugs
| Revlimid | 37 | $600,502 | $16,230 |
| Imbruvica | 37 | $481,565 | $13,015 |
| Kisqali | 26 | $355,999 | $13,692 |
| Afinitor | 13 | $208,896 | $16,069 |
| Inlyta | 15 | $183,640 | $12,243 |
| Jakafi | 12 | $175,409 | $14,617 |
| Procrit | 46 | $174,592 | $3,795 |
| Nerlynx | 12 | $97,670 | $8,139 |
| Imatinib Mesylate | 14 | $77,191 | $5,514 |
| Lupron Depot | 21 | $46,070 | $2,194 |
| Faslodex | 11 | $26,621 | $2,420 |
| Erlotinib | 12 | $21,509 | $1,792 |
| Fulvestrant | 11 | $20,944 | $1,904 |
| Exemestane | 74 | $20,809 | $281 |
| Xarelto | 26 | $13,534 | $521 |
| Eliquis | 22 | $10,667 | $485 |
| Letrozole | 366 | $6,435 | $18 |
| Zoledronic Acid | 15 | $1,941 | $129 |
| Tamoxifen Citrate | 30 | $1,541 | $51 |
| Hydroxyurea | 51 | $1,426 | $28 |
| Anastrozole | 80 | $1,264 | $16 |
| Dexamethasone | 42 | $489 | $12 |
| Bicalutamide | 17 | $470 | $28 |
| Metoclopramide | 25 | $89 | $4 |
| Prednisone | 11 | $58 | $5 |
| Diphenhydramine | 17 | $43 | $3 |
| Dexamethasone Sodium Phosphate | 12 | $40 | $3 |
| Famotidine | 12 | $29 | $2 |
2019: 29 drugs
| Revlimid | 43 | $668,865 | $15,555 |
| Imbruvica | 31 | $373,844 | $12,059 |
| Jakafi | 24 | $333,575 | $13,899 |
| Keytruda | 32 | $320,664 | $10,021 |
| Afinitor | 16 | $256,185 | $16,012 |
| Procrit | 49 | $196,958 | $4,020 |
| Ibrance | 14 | $172,726 | $12,338 |
| Nerlynx | 17 | $121,861 | $7,168 |
| Herceptin | 15 | $86,750 | $5,783 |
| Xgeva | 30 | $71,589 | $2,386 |
| Zarxio | 45 | $60,299 | $1,340 |
| Lupron Depot | 12 | $46,771 | $3,898 |
| Imatinib Mesylate | 12 | $45,891 | $3,824 |
| Faslodex | 13 | $38,070 | $2,928 |
| Exemestane | 82 | $35,769 | $436 |
| Letrozole | 388 | $5,720 | $15 |
| Anagrelide | 15 | $4,237 | $282 |
| Cyclophosphamide | 12 | $2,333 | $194 |
| Tamoxifen Citrate | 34 | $1,897 | $56 |
| Anastrozole | 74 | $1,463 | $20 |
| Hydroxyurea | 45 | $1,175 | $26 |
| Bicalutamide | 15 | $603 | $40 |
| Dexamethasone | 31 | $344 | $11 |
| Penicillin V | 14 | $275 | $20 |
| Hydrocodone-Acetaminophen | 12 | $154 | $13 |
| Ciprofloxacin | 19 | $106 | $6 |
| Metoclopramide | 32 | $94 | $3 |
| Prednisone | 11 | $39 | $4 |
| Famotidine | 12 | $23 | $2 |
2018: 36 drugs
| Revlimid | 40 | $615,655 | $15,391 |
| Imbruvica | 30 | $323,447 | $10,782 |
| Jakafi | 24 | $311,899 | $12,996 |
| Ibrance | 24 | $269,872 | $11,245 |
| Keytruda | 24 | $233,363 | $9,723 |
| Avastin | 39 | $222,473 | $5,704 |
| Herceptin | 40 | $211,879 | $5,297 |
| Perjeta | 23 | $137,850 | $5,993 |
| Nerlynx | 12 | $132,958 | $11,080 |
| Procrit | 37 | $130,947 | $3,539 |
| Imatinib Mesylate | 13 | $104,279 | $8,021 |
| Zarxio | 63 | $88,374 | $1,403 |
| Gleevec | 11 | $60,813 | $5,528 |
| Lupron Depot | 14 | $27,471 | $1,962 |
| Xgeva | 11 | $25,662 | $2,333 |
| Exemestane | 68 | $23,594 | $347 |
| Eliquis | 11 | $5,445 | $495 |
| Letrozole | 413 | $5,272 | $13 |
| Anagrelide | 23 | $3,754 | $163 |
| Cyclophosphamide | 13 | $3,090 | $238 |
| Zoledronic Acid | 13 | $2,965 | $228 |
| Tamoxifen Citrate | 56 | $2,031 | $36 |
| Oxaliplatin | 16 | $1,731 | $108 |
| Hydroxyurea | 58 | $1,364 | $24 |
| Anastrozole | 67 | $966 | $14 |
| Dexamethasone | 41 | $306 | $7 |
| Ondansetron | 36 | $298 | $8 |
| Metoclopramide | 41 | $146 | $4 |
| Tamsulosin | 11 | $143 | $13 |
| Hydroxyzine | 16 | $133 | $8 |
| Ciprofloxacin | 18 | $129 | $7 |
| Dexamethasone Sodium Phosphate | 31 | $74 | $2 |
| Prednisone | 16 | $73 | $5 |
| Magnesium Sulfate | 18 | $70 | $4 |
| Diphenhydramine | 24 | $54 | $2 |
| Famotidine | 30 | $49 | $2 |
2017: 32 drugs
| Revlimid | 37 | $527,733 | $14,263 |
| Ibrance | 25 | $280,766 | $11,231 |
| Nexavar | 21 | $256,597 | $12,219 |
| Avastin | 47 | $252,515 | $5,373 |
| Jakafi | 13 | $151,716 | $11,670 |
| Imbruvica | 13 | $144,654 | $11,127 |
| Procrit | 44 | $141,641 | $3,219 |
| Gleevec | 17 | $134,448 | $7,909 |
| Herceptin | 16 | $78,158 | $4,885 |
| Zarxio | 53 | $68,696 | $1,296 |
| Exemestane | 42 | $22,866 | $544 |
| Exjade | 12 | $13,011 | $1,084 |
| Anagrelide | 32 | $6,626 | $207 |
| Eliquis | 15 | $6,054 | $404 |
| Letrozole | 339 | $3,978 | $12 |
| Cyclophosphamide | 11 | $2,465 | $224 |
| Oxaliplatin | 12 | $1,992 | $166 |
| Dutasteride | 11 | $1,608 | $146 |
| Hydroxyurea | 61 | $1,561 | $26 |
| Tamoxifen Citrate | 37 | $1,232 | $33 |
| Anastrozole | 79 | $921 | $12 |
| Celecoxib | 12 | $549 | $46 |
| Ondansetron | 29 | $352 | $12 |
| Dexamethasone | 39 | $186 | $5 |
| Tamsulosin | 12 | $180 | $15 |
| Ciprofloxacin | 20 | $170 | $9 |
| Metoclopramide | 43 | $153 | $4 |
| Prednisone | 12 | $76 | $6 |
| Magnesium Sulfate | 12 | $52 | $4 |
| Dexamethasone Sodium Phosphate | 12 | $30 | $2 |
| Diphenhydramine | 12 | $21 | $2 |
| Famotidine | 12 | $19 | $2 |
2016: 23 drugs
| Revlimid | 32 | $364,836 | $11,401 |
| Ibrance | 20 | $212,218 | $10,611 |
| Gleevec | 15 | $132,965 | $8,864 |
| Avastin | 32 | $123,775 | $3,868 |
| Thalomid | 15 | $110,307 | $7,354 |
| Promacta | 11 | $77,596 | $7,054 |
| Procrit | 19 | $59,606 | $3,137 |
| Neupogen | 13 | $47,594 | $3,661 |
| Anagrelide | 45 | $12,163 | $270 |
| Exjade | 11 | $10,621 | $966 |
| Exemestane | 29 | $9,341 | $322 |
| Letrozole | 360 | $5,310 | $15 |
| Cyclophosphamide | 12 | $2,590 | $216 |
| Hydroxyurea | 37 | $1,144 | $31 |
| Tamoxifen Citrate | 54 | $1,046 | $19 |
| Anastrozole | 101 | $942 | $9 |
| Cyclosporine Modified | 13 | $931 | $72 |
| Dexamethasone | 61 | $269 | $4 |
| Ondansetron Odt | 14 | $212 | $15 |
| Prednisone | 20 | $155 | $8 |
| Metoclopramide | 47 | $151 | $3 |
| Ciprofloxacin | 14 | $92 | $7 |
| Furosemide | 12 | $47 | $4 |
2015: 29 drugs
| Revlimid | 32 | $327,160 | $10,224 |
| Tarceva | 28 | $181,442 | $6,480 |
| Thalomid | 21 | $155,094 | $7,385 |
| Gleevec | 14 | $144,683 | $10,335 |
| Procrit | 43 | $140,466 | $3,267 |
| Avastin | 24 | $121,808 | $5,075 |
| Velcade | 12 | $72,733 | $6,061 |
| Rituxan | 15 | $69,637 | $4,642 |
| Kadcyla | 12 | $65,379 | $5,448 |
| Neupogen | 13 | $35,535 | $2,733 |
| Femara | 22 | $14,930 | $679 |
| Exemestane | 38 | $11,996 | $316 |
| Anagrelide | 50 | $10,101 | $202 |
| Aromasin | 13 | $8,868 | $682 |
| Letrozole | 353 | $4,435 | $13 |
| Cyclophosphamide | 13 | $2,485 | $191 |
| Hydroxyurea | 53 | $1,243 | $23 |
| Tamoxifen Citrate | 39 | $946 | $24 |
| Anastrozole | 99 | $886 | $9 |
| Cyclosporine Modified | 12 | $745 | $62 |
| Hydrocodone-Acetaminophen | 20 | $679 | $34 |
| Ondansetron Odt | 18 | $432 | $24 |
| Metoclopramide | 67 | $259 | $4 |
| Warfarin | 25 | $239 | $10 |
| Ciprofloxacin | 24 | $224 | $9 |
| Prednisone | 18 | $197 | $11 |
| Dexamethasone | 53 | $197 | $4 |
| Ondansetron | 11 | $149 | $14 |
| Dicyclomine | 15 | $66 | $4 |
2014: 38 drugs
| Revlimid | 26 | $246,333 | $9,474 |
| Herceptin | 38 | $232,108 | $6,108 |
| Procrit | 64 | $216,617 | $3,385 |
| Xtandi | 16 | $134,271 | $8,392 |
| Thalomid | 17 | $123,725 | $7,278 |
| Jakafi | 11 | $98,740 | $8,976 |
| Zytiga | 16 | $93,628 | $5,852 |
| Leukine | 29 | $79,684 | $2,748 |
| Tarceva | 15 | $79,250 | $5,283 |
| Kadcyla | 16 | $63,068 | $3,942 |
| Neupogen | 12 | $33,180 | $2,765 |
| Exemestane | 47 | $16,910 | $360 |
| Femara | 13 | $8,154 | $627 |
| Aromasin | 12 | $6,969 | $581 |
| Letrozole | 243 | $6,031 | $25 |
| Anagrelide | 42 | $5,706 | $136 |
| Gemcitabine | 19 | $4,238 | $223 |
| Emend | 12 | $3,729 | $311 |
| Linzess | 11 | $2,636 | $240 |
| Fentanyl | 16 | $2,588 | $162 |
| Anastrozole | 100 | $2,534 | $25 |
| Celebrex | 11 | $2,212 | $201 |
| Carboplatin | 22 | $1,924 | $87 |
| Paclitaxel | 11 | $1,375 | $125 |
| Hydroxyurea | 71 | $1,372 | $19 |
| Tamoxifen Citrate | 44 | $847 | $19 |
| Hydrocodone-Acetaminophen | 34 | $766 | $23 |
| Voltaren | 18 | $760 | $42 |
| Valacyclovir | 12 | $607 | $51 |
| Warfarin | 39 | $374 | $10 |
| Ondansetron | 23 | $354 | $15 |
| Tamsulosin | 14 | $349 | $25 |
| Prednisone | 42 | $339 | $8 |
| Dexamethasone | 54 | $249 | $5 |
| Metoclopramide | 56 | $237 | $4 |
| Ciprofloxacin | 28 | $215 | $8 |
| Dicyclomine | 15 | $110 | $7 |
| Azithromycin | 11 | $93 | $8 |
2013: 36 drugs
| Procrit | 49 | $163,395 | $3,335 |
| Revlimid | 18 | $155,760 | $8,653 |
| Thalomid | 23 | $150,832 | $6,558 |
| Rituxan | 18 | $129,279 | $7,182 |
| Zytiga | 21 | $113,716 | $5,415 |
| Xtandi | 12 | $94,360 | $7,863 |
| Avastin | 21 | $80,557 | $3,836 |
| Leukine | 29 | $75,620 | $2,608 |
| Tarceva | 24 | $68,794 | $2,866 |
| Herceptin | 19 | $65,820 | $3,464 |
| Remicade | 15 | $54,988 | $3,666 |
| Cyclophosphamide | 22 | $9,610 | $437 |
| Exemestane | 38 | $8,338 | $219 |
| Femara | 15 | $8,016 | $534 |
| Aromasin | 14 | $6,953 | $497 |
| Letrozole | 230 | $6,732 | $29 |
| Anagrelide | 39 | $4,319 | $111 |
| Fentanyl | 16 | $3,117 | $195 |
| Anastrozole | 106 | $3,103 | $29 |
| Hydroxyurea | 45 | $1,308 | $29 |
| Valacyclovir | 16 | $1,090 | $68 |
| Tamoxifen Citrate | 39 | $525 | $13 |
| Warfarin | 45 | $522 | $12 |
| Megestrol Acetate | 16 | $483 | $30 |
| Hydrocodone-Acetaminophen | 30 | $475 | $16 |
| Voltaren | 11 | $430 | $39 |
| Prochlorperazine Maleate | 45 | $390 | $9 |
| Prednisone | 53 | $228 | $4 |
| Dexamethasone | 60 | $223 | $4 |
| Ciprofloxacin | 24 | $220 | $9 |
| Potassium Chloride | 11 | $202 | $18 |
| Tamsulosin | 11 | $187 | $17 |
| Ondansetron | 13 | $131 | $10 |
| Metoclopramide | 18 | $84 | $5 |
| Tramadol | 13 | $78 | $6 |
| Allopurinol | 16 | $58 | $4 |
Money from drug and device companies
$6,508 in 2025
| 2025 | 51 | 249 | None | $6,508 |
| 2024 | 48 | 220 | None | $5,651 |
| 2023 | 48 | 226 | None | $6,055 |
| 2022 | 46 | 225 | None | $5,079 |
| 2021 | 44 | 252 | None | $4,726 |
| 2020 | 40 | 212 | None | $4,853 |
| 2019 | 37 | 246 | None | $5,102 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Pfizer | Elrexfio | $551 | 24 payments
|
| AstraZeneca Pharmaceuticals LP | Calquence | $478 | 17 payments
|
| Abbvie | Epkinly | $408 | 9 payments
|
| Gilead Sciences | Trodelvy | $247 | 9 payments
|
| GlaxoSmithKline | Ojjaara | $238 | 5 payments
|
| Janssen Biotech | Rybrevant | $233 | 9 payments
|
See all 245 published payments
| Incyte | Meals · 2025-12-29 | Monjuvi | $29 |
| Abbvie | Meals · 2025-12-19 | Elahere | $32 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-18 | Calquence | $29 |
| Ipsen Biopharmaceuticals | Meals · 2025-12-17 | Onivyde | $30 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-16 | None | $9 |
| Stemline Therapeutics | Meals · 2025-12-16 | Orserdu | $38 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-15 | Opdivo | $23 |
| Syndax Pharmaceuticals | Meals · 2025-12-12 | None | $29 |
| Abbvie | Meals · 2025-12-11 | Venclexta | $124 |
| Nuvation Bio | Meals · 2025-12-11 | Ibtrozi | $19 |
| Genzyme | Meals · 2025-12-10 | Sarclisa | $41 |
| Ipsen Biopharmaceuticals | Meals · 2025-12-08 | Somatuline Depot | $26 |
| Genzyme | Meals · 2025-12-08 | Wayrilz | $5 |
| Janssen Biotech | Meals · 2025-12-05 | Darzalex | $30 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-04 | Tagrisso | $33 |
| Pfizer | Meals · 2025-12-04 | Elrexfio | $9 |
| TerSera Therapeutics | Meals · 2025-12-02 | Zoladex | $34 |
| Merck Sharp & Dohme | Meals · 2025-12-01 | Keytruda | $33 |
| Agios Pharmaceuticals | Meals · 2025-11-26 | Pyrukynd | $16 |
| Array Biopharma | Meals · 2025-11-25 | Lorbrena | $27 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-24 | None | $23 |
| Sobi | Meals · 2025-11-21 | Vonjo | $36 |
| Array Biopharma | Meals · 2025-11-20 | Lorbrena | $7 |
| Array Biopharma | Meals · 2025-11-20 | Lorbrena | $4 |
| Genzyme | Meals · 2025-11-20 | Wayrilz | $33 |
| Stemline Therapeutics | Meals · 2025-11-19 | Orserdu | $25 |
| Astellas Pharma US | Meals · 2025-11-18 | Xtandi | $4 |
| Abbvie | Meals · 2025-11-17 | Epkinly | $21 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-14 | Calquence | $24 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-13 | Opdivo | $26 |
| Daiichi Sankyo | Meals · 2025-11-13 | Datroway | $12 |
| Pfizer | Meals · 2025-11-12 | Tivdak | $24 |
| Janssen Biotech | Meals · 2025-11-11 | Tecvayli | $25 |
| Deciphera Pharmaceuticals | Meals · 2025-11-10 | Qinlock | $23 |
| Incyte | Meals · 2025-11-07 | Monjuvi | $28 |
| Progenics Pharmaceuticals | Meals · 2025-11-06 | Pylarify | $24 |
| Gilead Sciences | Meals · 2025-11-04 | Trodelvy | $29 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-03 | Enhertu | $25 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-31 | Opdualag | $24 |
| Celgene | Meals · 2025-10-30 | Reblozyl | $25 |
| Genmab U.S. | Meals · 2025-10-29 | Epkinly | $34 |
| Incyte | Meals · 2025-10-28 | Jakafi | $26 |
| Syndax Pharmaceuticals | Meals · 2025-10-24 | None | $31 |
| Iovance Biotherapeutics | Meals · 2025-10-24 | Amtagvi | $18 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-20 | None | $23 |
| Novartis Pharmaceuticals | Meals · 2025-10-20 | Pluvicto | $20 |
| Daiichi Sankyo | Meals · 2025-10-17 | Datroway | $6 |
| Daiichi Sankyo | Meals · 2025-10-17 | Datroway | $4 |
| Array Biopharma | Meals · 2025-10-17 | Braftovi | $19 |
| Daiichi Sankyo | Meals · 2025-10-16 | Datroway | $4 |
| PharmaEssentia USA | Meals · 2025-10-16 | Besremi | $25 |
| GlaxoSmithKline | Meals · 2025-10-15 | Ojjaara | $34 |
| Ipsen Biopharmaceuticals | Meals · 2025-10-14 | Onivyde | $31 |
| TerSera Therapeutics | Meals · 2025-10-13 | Zoladex | $29 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-10 | Calquence | $20 |
| Janssen Biotech | Meals · 2025-10-09 | Talvey | $32 |
| Fennec Pharmaceuticals | Meals · 2025-10-07 | Fyarro | $25 |
| Array Biopharma | Meals · 2025-10-06 | Braftovi | $19 |
| Pfizer | Meals · 2025-10-03 | Ibrance | $18 |
| Merck Sharp & Dohme | Meals · 2025-10-02 | Keytruda | $29 |
| Genzyme | Meals · 2025-10-01 | Wayrilz | $40 |
| Regeneron Healthcare Solutions | Meals · 2025-09-30 | Lynozyfic | $24 |
| Pfizer | Meals · 2025-09-29 | Elrexfio | $2 |
| Geron | Meals · 2025-09-29 | Rytelo | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-25 | Calquence | $25 |
| Janssen Biotech | Meals · 2025-09-24 | Erleada | $35 |
| Alexion Pharmaceuticals | Meals · 2025-09-23 | Ultomiris | $23 |
| Janssen Biotech | Meals · 2025-09-22 | Rybrevant | $29 |
| Lilly USA | Meals · 2025-09-22 | Verzenio | $8 |
| Geron | Meals · 2025-09-22 | Rytelo | $120 |
| Merck Sharp & Dohme | Meals · 2025-09-18 | Keytruda | $34 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-09-16 | None | $30 |
| Pfizer | Meals · 2025-09-16 | Ibrance | $15 |
| Sobi | Meals · 2025-09-16 | Vonjo | $20 |
| Astellas Pharma US | Meals · 2025-09-12 | Xtandi | $19 |
| Celgene | Meals · 2025-09-11 | Breyanzi | $29 |
| Lilly USA | Meals · 2025-09-11 | Verzenio | $11 |
| Lilly USA | Meals · 2025-09-11 | Verzenio | $3 |
| Agios Pharmaceuticals | Meals · 2025-09-10 | Pyrukynd | $20 |
| Exelixis | Meals · 2025-09-08 | Cabometyx | $20 |
| Pfizer | Meals · 2025-09-08 | Elrexfio | $24 |
| Recordati Rare Diseases Inc. | Meals · 2025-09-04 | Sylvant | $68 |
| Genentech USA | Meals · 2025-09-04 | Venclexta | $34 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-08-28 | None | $29 |
| Stemline Therapeutics | Meals · 2025-08-27 | Elzonris | $20 |
| SpringWorks Therapeutics | Meals · 2025-08-26 | Ogsiveo | $19 |
| Gilead Sciences | Meals · 2025-08-26 | Trodelvy | $32 |
| Pfizer | Meals · 2025-08-25 | Tivdak | $21 |
| Stemline Therapeutics | Meals · 2025-08-25 | Orserdu | $35 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-22 | Calquence | $7 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-22 | Calquence | $19 |
| Merck Sharp & Dohme | Meals · 2025-08-21 | Keytruda | $27 |
| Sobi | Meals · 2025-08-20 | Vonjo | $20 |
| Pfizer | Meals · 2025-08-19 | Tivdak | $39 |
| Abbvie | Meals · 2025-08-18 | Epkinly | $125 |
| Exelixis | Meals · 2025-08-18 | Cabometyx | $22 |
| Daiichi Sankyo | Meals · 2025-08-15 | Datroway | $7 |
| Daiichi Sankyo | Meals · 2025-08-14 | Datroway | $7 |
| Abbvie | Meals · 2025-08-13 | Elahere | $24 |
| Ipsen Biopharmaceuticals | Meals · 2025-08-13 | Onivyde | $25 |
| Gilead Sciences | Meals · 2025-08-11 | Trodelvy | $33 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-08-08 | Stivarga | $16 |
| Novartis Pharmaceuticals | Meals · 2025-08-04 | Kisqali | $19 |
| Puma Biotechnology | Meals · 2025-08-04 | Nerlynx | $16 |
| Pfizer | Meals · 2025-07-29 | Elrexfio | $15 |
| EMD Serono | Meals · 2025-07-28 | None | $32 |
| GlaxoSmithKline | Meals · 2025-07-22 | Ojjaara | $31 |
| Daiichi Sankyo | Meals · 2025-07-21 | Enhertu | $28 |
| Daiichi Sankyo | Meals · 2025-07-17 | Enhertu | $1 |
| Daiichi Sankyo | Meals · 2025-07-17 | Enhertu | $9 |
| Coherus Oncology | Meals · 2025-07-17 | Loqtorzi | $22 |
| Lilly USA | Meals · 2025-07-15 | Verzenio | $33 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-07-14 | Nubeqa | $27 |
| Pfizer | Meals · 2025-07-14 | Xtandi | $29 |
| Pfizer | Meals · 2025-07-14 | Xtandi | $2 |
| GlaxoSmithKline | Meals · 2025-07-11 | Jemperli | $30 |
| Alexion Pharmaceuticals | Meals · 2025-07-10 | Ultomiris | $28 |
| Celgene | Meals · 2025-07-09 | Reblozyl | $22 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-07 | None | $18 |
| Pfizer | Meals · 2025-07-07 | Elrexfio | $119 |
| Progenics Pharmaceuticals | Meals · 2025-07-03 | Pylarify | $29 |
| Abbvie | Meals · 2025-07-02 | Emrelis | $19 |
| Eisai | Meals · 2025-07-01 | Lenvima | $19 |
| Pfizer | Meals · 2025-06-30 | Padcev | $30 |
| Incyte | Meals · 2025-06-27 | Monjuvi | $25 |
| Lilly USA | Meals · 2025-06-26 | Verzenio | $7 |
| Lilly USA | Meals · 2025-06-26 | Verzenio | $4 |
| Pfizer | Meals · 2025-06-26 | Ibrance | $24 |
| Puma Biotechnology | Meals · 2025-06-26 | Nerlynx | $24 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-06-24 | Nubeqa | $15 |
| Merck Sharp & Dohme | Meals · 2025-06-23 | Keytruda | $29 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-06-19 | None | $22 |
| Pfizer | Meals · 2025-06-18 | Tivdak | $37 |
| Daiichi Sankyo | Meals · 2025-06-16 | Enhertu | $7 |
| Exelixis | Meals · 2025-06-16 | Cabometyx | $32 |
| Recordati Rare Diseases Inc. | Meals · 2025-06-11 | Sylvant | $21 |
| Geron | Meals · 2025-06-10 | Rytelo | $31 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-06-09 | Opdualag | $26 |
| GlaxoSmithKline | Meals · 2025-06-09 | Ojjaara | $24 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-06-06 | Iclusig | $34 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-05 | Tagrisso | $25 |
| Pfizer | Meals · 2025-06-04 | Tivdak | $2 |
| SpringWorks Therapeutics | Meals · 2025-06-03 | Ogsiveo | $20 |
| Merck Sharp & Dohme | Meals · 2025-06-02 | Keytruda | $33 |
| TerSera Therapeutics | Meals · 2025-05-29 | Zoladex | $26 |
| Janssen Biotech | Meals · 2025-05-28 | Rybrevant | $17 |
| Ipsen Biopharmaceuticals | Meals · 2025-05-28 | Onivyde | $25 |
| Abbvie | Meals · 2025-05-27 | Epkinly | $13 |
| Genmab U.S. | Meals · 2025-05-23 | Epkinly | $32 |
| Array Biopharma | Meals · 2025-05-22 | Lorbrena | $25 |
| Pfizer | Meals · 2025-05-21 | Elrexfio | $17 |
| Agios Pharmaceuticals | Meals · 2025-05-20 | Pyrukynd | $16 |
| Lilly USA | Meals · 2025-05-19 | Verzenio | $31 |
| Deciphera Pharmaceuticals | Meals · 2025-05-19 | Qinlock | $30 |
| Stemline Therapeutics | Meals · 2025-05-16 | Orserdu | $35 |
| Gilead Sciences | Meals · 2025-05-15 | Trodelvy | $28 |
| Lilly USA | Meals · 2025-05-13 | Verzenio | $27 |
| Fennec Pharmaceuticals | Meals · 2025-05-13 | Fyarro | $15 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-12 | Iclusig | $29 |
| Astellas Pharma US | Meals · 2025-05-12 | Xospata | $118 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-09 | Calquence | $24 |
| Daiichi Sankyo | Meals · 2025-05-08 | Enhertu | $26 |
| Incyte | Meals · 2025-05-05 | Jakafi | $26 |
| Abbvie | Meals · 2025-05-02 | Elahere | $19 |
| Celgene | Meals · 2025-05-01 | Reblozyl | $19 |
| Gilead Sciences | Meals · 2025-04-30 | Trodelvy | $29 |
| Azurity Pharmaceuticals | Meals · 2025-04-30 | Danziten | $14 |
| Gilead Sciences | Meals · 2025-04-29 | Trodelvy | $23 |
| Pfizer | Meals · 2025-04-25 | Elrexfio | $8 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-04-24 | None | $24 |
| Blueprint Medicines | Meals · 2025-04-24 | Ayvakit | $41 |
| Novartis Pharmaceuticals | Meals · 2025-04-21 | Scemblix | $22 |
| Pfizer | Meals · 2025-04-18 | Elrexfio | $22 |
| Agios Pharmaceuticals | Meals · 2025-04-17 | Pyrukynd | $34 |
| Aveo Pharmaceuticals | Education · 2025-04-16 | Fotivda | $91 |
| Alexion Pharmaceuticals | Meals · 2025-04-15 | Ultomiris | $23 |
| Genzyme | Meals · 2025-04-15 | None | $17 |
| Pfizer | Meals · 2025-04-14 | Xtandi | $10 |
| Janssen Biotech | Meals · 2025-04-11 | Rybrevant | $12 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-10 | Enhertu | $31 |
| Puma Biotechnology | Meals · 2025-04-09 | Nerlynx | $29 |
| Daiichi Sankyo | Meals · 2025-04-08 | Enhertu | $24 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-07 | None | $24 |
| Merck Sharp & Dohme | Meals · 2025-04-04 | Lynparza | $29 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-03 | None | $14 |
| Janssen Biotech | Meals · 2025-03-31 | Carvykti | $25 |
| Pfizer | Meals · 2025-03-31 | Xtandi | $8 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-27 | Opdivo | $22 |
| Sobi | Meals · 2025-03-26 | Vonjo | $19 |
| Sobi | Meals · 2025-03-26 | Vonjo | $4 |
| Ipsen Biopharmaceuticals | Meals · 2025-03-25 | Onivyde | $25 |
| Sobi | Meals · 2025-03-25 | Vonjo | $1 |
| Abbvie | Meals · 2025-03-24 | Elahere | $31 |
| Eisai | Meals · 2025-03-20 | Lenvima | $22 |
| Accord Healthcare | Meals · 2025-03-20 | Camcevi | $18 |
| Agios Pharmaceuticals | Meals · 2025-03-18 | Pyrukynd | $20 |
| GlaxoSmithKline | Meals · 2025-03-17 | Ojjaara | $120 |
| TerSera Therapeutics | Meals · 2025-03-17 | Zoladex | $24 |
| SpringWorks Therapeutics | Meals · 2025-03-14 | Ogsiveo | $22 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-13 | Fruzaqla | $33 |
| Pfizer | Meals · 2025-03-11 | Tivdak | $30 |
| Taiho Oncology | Meals · 2025-03-10 | Lonsurf | $30 |
| Karyopharm Therapeutics | Meals · 2025-03-07 | Xpovio | $30 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-06 | Iclusig | $26 |
| Stemline Therapeutics | Meals · 2025-03-04 | Orserdu | $28 |
| PharmaEssentia USA | Meals · 2025-03-03 | Besremi | $29 |
| Novartis Pharmaceuticals | Meals · 2025-02-28 | Kisqali | $31 |
| Pfizer | Meals · 2025-02-27 | Bosulif | $21 |
| Lilly USA | Meals · 2025-02-26 | Verzenio | $32 |
| Deciphera Pharmaceuticals | Meals · 2025-02-25 | Qinlock | $23 |
| EMD Serono | Meals · 2025-02-24 | None | $32 |
| Celgene | Meals · 2025-02-21 | Reblozyl | $20 |
| Janssen Biotech | Meals · 2025-02-20 | Rybrevant | $28 |
| Gilead Sciences | Meals · 2025-02-18 | Trodelvy | $34 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-02-17 | Nubeqa | $22 |
| Celgene | Meals · 2025-02-13 | Opdualag | $16 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-13 | Imfinzi | $122 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-02-13 | Nubeqa | $16 |
| SpringWorks Therapeutics | Meals · 2025-02-13 | Ogsiveo | $24 |
| Adc Therapeutics America | Meals · 2025-02-12 | Zynlonta | $35 |
| Astellas Pharma US | Meals · 2025-02-11 | Xtandi | $16 |
| Genentech USA | Meals · 2025-02-10 | Venclexta | $31 |
| Regeneron Healthcare Solutions | Meals · 2025-02-07 | Libtayo | $36 |
| Exelixis | Meals · 2025-02-06 | Cabometyx | $36 |
| Gilead Sciences | Meals · 2025-02-05 | Trodelvy | $5 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-03 | Enhertu | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-31 | Calquence | $19 |
| Lilly USA | Meals · 2025-01-30 | Verzenio | $10 |
| Ipsen Biopharmaceuticals | Meals · 2025-01-30 | Somatuline Depot | $28 |
| Eisai | Meals · 2025-01-29 | Lenvima | $20 |
| Genmab U.S. | Meals · 2025-01-27 | Epkinly | $32 |
| Sobi | Education · 2025-01-24 | None | $80 |
| Agios Pharmaceuticals | Meals · 2025-01-23 | Pyrukynd | $26 |
| Gilead Sciences | Meals · 2025-01-21 | Trodelvy | $34 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-17 | Lynparza | $14 |
| Eisai | Meals · 2025-01-16 | Lenvima | $26 |
| Ipsen Biopharmaceuticals | Meals · 2025-01-15 | Onivyde | $28 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-01-14 | None | $19 |
| Genentech USA | Meals · 2025-01-13 | Itovebi | $32 |
| Array Biopharma | Meals · 2025-01-10 | Xalkori | $27 |
| Pfizer | Meals · 2025-01-07 | Tivdak | $27 |
| Deciphera Pharmaceuticals | Meals · 2025-01-06 | Qinlock | $21 |
| Sobi | Meals · 2025-01-03 | Vonjo | $34 |
| Sobi | Meals · 2025-01-03 | Vonjo | $1 |
| Sun Pharmaceutical Industries | Meals · 2025-01-02 | Yonsa | $29 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $5,651
| AstraZeneca Pharmaceuticals LP | Enhertu | $495 | 16 payments
|
| Pfizer | Bosulif | $395 | 25 payments
|
| Merck Sharp & Dohme | Keytruda | $349 | 13 payments
|
| Lilly USA | Verzenio | $277 | 11 payments
|
| Gilead Sciences | Trodelvy | $263 | 12 payments
|
| Incyte | Monjuvi | $261 | 6 payments
|
| Celgene | Reblozyl | $210 | 9 payments
|
| Takeda Pharmaceuticals U.S.A. | Iclusig | $201 | 8 payments
|
| GlaxoSmithKline | Ojjaara | $194 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $192 | 9 payments
|
| Abbvie | Imbruvica | $189 | 7 payments
|
| Novartis Pharmaceuticals | Kisqali | $157 | 9 payments
|
| Janssen Biotech | Rybrevant | $155 | 6 payments
|
| Jazz Pharmaceuticals | Vyxeos | $149 | 2 payments
|
| Sobi | Vonjo | $147 | 2 payments
|
| Exelixis | Cabometyx | $136 | 5 payments
|
| Taiho Oncology | Lonsurf | $126 | 5 payments
|
| PharmaEssentia USA | Besremi | $114 | 4 payments
|
| EMD Serono | None | $107 | 4 payments
|
| Astellas Pharma US | Padcev | $103 | 4 payments
|
| Ipsen Biopharmaceuticals | Onivyde | $103 | 4 payments
|
| Karyopharm Therapeutics | Xpovio | $99 | 3 payments
|
| Genmab U.S. | Epkinly | $90 | 3 payments
|
| Daiichi Sankyo | Enhertu | $87 | 3 payments
|
| Blueprint Medicines | Ayvakit | $83 | 3 payments
|
| Puma Biotechnology | None | $74 | 3 payments
|
| Array Biopharma | Xalkori | $74 | 4 payments
|
| Eisai | Lenvima | $73 | 3 payments
|
| Sun Pharmaceutical Industries | Yonsa | $71 | 3 payments
|
| Genentech USA | Venclexta | $67 | 3 payments
|
| Regeneron Healthcare Solutions | Libtayo | $64 | 2 payments
|
| SpringWorks Therapeutics | Ogsiveo | $60 | 3 payments
|
| Alexion Pharmaceuticals | Ultomiris | $55 | 2 payments
|
| Blue Earth Diagnostics | Posluma | $52 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $52 | 2 payments
|
| TerSera Therapeutics | Zoladex | $50 | 2 payments
|
| Pharmacosmos Therapeutics | Monoferric | $34 | 1 payment
|
| Deciphera Pharmaceuticals | Qinlock | $31 | 1 payment
|
| Myriad Genetic Laboratories | Myrisk | $29 | 1 payment
|
| Verity Pharmaceuticals | Trelstar | $28 | 1 payment
|
| Stemline Therapeutics | Orserdu | $28 | 1 payment
|
| Tempus AI | None | $25 | 1 payment
|
| Mirati Therapeutics | Krazati | $21 | 1 payment
|
| Fennec Pharmaceuticals | Pedmark | $19 | 1 payment
|
| Agios Pharmaceuticals | Pyrukynd | $17 | 1 payment
|
| BeiGene USA | Brukinsa | $16 | 1 payment
|
| Cumberland Pharmaceuticals | Sancuso | $16 | 1 payment
|
| ADC Therapeutics America | None | $15 | 1 payment
|
2023: $6,055
| Incyte | Jakafi | $520 | 17 payments
|
| Merck Sharp & Dohme | Keytruda | $409 | 17 payments
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $386 | 11 payments
|
| Celgene | Reblozyl | $362 | 16 payments
|
| Novartis Pharmaceuticals | Kisqali | $344 | 11 payments
|
| Seagen | Adcetris | $304 | 12 payments
|
| Pfizer | Bosulif | $293 | 13 payments
|
| Genentech USA | Phesgo | $258 | 12 payments
|
| Karyopharm Therapeutics | Xpovio | $252 | 5 payments
|
| Genzyme | Sarclisa | $225 | 5 payments
|
| PharmaEssentia USA | Besremi | $200 | 5 payments
|
| Gilead Sciences | Trodelvy | $199 | 8 payments
|
| Janssen Scientific Affairs | Erleada | $145 | 1 payment
|
| Amgen | Nplate | $129 | 8 payments
|
| ImmunoGen | Elahere | $121 | 5 payments
|
| Genmab U.S. | Epkinly | $120 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $117 | 5 payments
|
| Janssen Biotech | Darzalex | $109 | 5 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $100 | 4 payments
|
| Array Biopharma | Xalkori | $100 | 5 payments
|
| Lilly USA | Verzenio | $93 | 4 payments
|
| Bayer Healthcare Pharmaceuticals | Stivarga | $89 | 4 payments
|
| Regeneron Healthcare Solutions | Libtayo | $82 | 3 payments
|
| Puma Biotechnology | None | $82 | 3 payments
|
| Taiho Oncology | Lonsurf | $81 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $74 | 3 payments
|
| Daiichi Sankyo | Enhertu | $72 | 3 payments
|
| Eisai | Lenvima | $66 | 3 payments
|
| Exelixis | Cabometyx | $65 | 3 payments
|
| Blueprint Medicines | Ayvakit | $57 | 2 payments
|
| Stemline Therapeutics | Orserdu | $53 | 2 payments
|
| Ipsen Biopharmaceuticals | Onivyde | $52 | 2 payments
|
| TerSera Therapeutics | Quzyttir | $51 | 2 payments
|
| GlaxoSmithKline | Zejula | $50 | 2 payments
|
| Sun Pharmaceutical Industries | Yonsa | $46 | 2 payments
|
| Rigel Pharmaceuticals | Rezlidhia | $44 | 2 payments
|
| Foundation Medicine | None | $42 | 2 payments
|
| Chiesi USA | Ferriprox | $40 | 2 payments
|
| Jazz Pharmaceuticals | Zepzelca | $29 | 1 payment
|
| Sobi | Doptelet | $26 | 1 payment
|
| Deciphera Pharmaceuticals | Qinlock | $26 | 1 payment
|
| EMD Serono | Bavencio | $25 | 1 payment
|
| Astellas Pharma US | Xospata | $25 | 1 payment
|
| AVEO Pharmaceuticals | Fotivda | $23 | 1 payment
|
| CTI BioPharma | Vonjo | $22 | 1 payment
|
| G1 Therapeutics | Cosela | $16 | 1 payment
|
| Tolmar | Eligard | $15 | 1 payment
|
| BeiGene USA | Brukinsa | $14 | 1 payment
|
2022: $5,079
| Novartis Pharmaceuticals | Kisqali | $533 | 13 payments
|
| Celgene | Pomalyst | $360 | 16 payments
|
| Exelixis | Cabometyx | $342 | 8 payments
|
| Pfizer | Ibrance | $280 | 15 payments
|
| Lilly USA | Verzenio | $220 | 10 payments
|
| Incyte | Jakafi | $217 | 10 payments
|
| Genentech USA | Venclexta | $208 | 15 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $205 | 9 payments
|
| Karyopharm Therapeutics | Xpovio | $203 | 7 payments
|
| Gilead Sciences | Trodelvy | $179 | 8 payments
|
| Merck Sharp & Dohme | Keytruda | $174 | 9 payments
|
| Seagen | Adcetris | $162 | 8 payments
|
| Array Biopharma | Braftovi | $150 | 7 payments
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $145 | 6 payments
|
| Janssen Biotech | Darzalex | $141 | 3 payments
|
| GlaxoSmithKline | Zejula | $136 | 5 payments
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $116 | 6 payments
|
| Amgen | Nplate | $114 | 5 payments
|
| Pharmacyclics LLC an AbbVie | Imbruvica | $104 | 4 payments
|
| Ipsen Biopharmaceuticals | Somatuline Depot | $95 | 4 payments
|
| Genzyme | Sarclisa | $90 | 4 payments
|
| Blueprint Medicines | Ayvakit | $80 | 3 payments
|
| Bayer HealthCare Pharmaceuticals | Stivarga | $79 | 4 payments
|
| Eisai | Lenvima | $70 | 4 payments
|
| TOLMAR Pharmaceuticals | Eligard | $58 | 3 payments
|
| Astellas Pharma US | Padcev | $54 | 3 payments
|
| Taiho Oncology | Lonsurf | $51 | 2 payments
|
| Alexion Pharmaceuticals | Ultomiris | $49 | 2 payments
|
| Daiichi Sankyo | Injectafer | $49 | 2 payments
|
| G1 Therapeutics | Cosela | $46 | 2 payments
|
| Rigel Pharmaceuticals | Tavalisse | $43 | 2 payments
|
| Regeneron Healthcare Solutions | Libtayo | $40 | 2 payments
|
| Foundation Medicine | Foundationone | $29 | 1 payment
|
| Abbvie | Venclexta | $26 | 1 payment
|
| PharmaEssentia USA | Besremi | $26 | 1 payment
|
| Puma Biotechnology | Nerlynx | $21 | 1 payment
|
| Jazz Pharmaceuticals | Zepzelca | $21 | 1 payment
|
| GE HealthCare | None | $20 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $20 | 1 payment
|
| Myovant Sciences | Orgovyx | $20 | 1 payment
|
| Macrogenics | Margenza | $19 | 1 payment
|
| MorphoSys US | Monjuvi | $19 | 1 payment
|
| Epizyme | Tazverik | $18 | 1 payment
|
| AVEO Pharmaceuticals | Fotivda | $18 | 1 payment
|
| Organon | Nexplanon | $15 | 2 payments
|
| Heron Therapeutics | Cinvanti | $13 | 1 payment
|
2021: $4,726
| Pfizer | Ibrance | $354 | 18 payments
|
| Amgen | Lumakras | $296 | 10 payments
|
| Karyopharm Therapeutics | Xpovio | $284 | 10 payments
|
| Seagen | Adcetris | $252 | 12 payments
|
| Genzyme | Libtayo | $249 | 12 payments
|
| Genentech USA | Venclexta | $246 | 12 payments
|
| Bayer HealthCare Pharmaceuticals | Stivarga | $226 | 12 payments
|
| Exelixis | Cabometyx | $214 | 10 payments
|
| Kite Pharma | None | $198 | 7 payments
|
| Lilly USA | Verzenio | $191 | 10 payments
|
| Incyte | Jakafi | $188 | 8 payments
|
| Merck Sharp & Dohme | Keytruda | $178 | 10 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $166 | 8 payments
|
| Celgene | Onureg | $165 | 9 payments
|
| GlaxoSmithKline | Zejula | $118 | 5 payments
|
| Blueprint Medicines | Gavreto | $115 | 5 payments
|
| Novartis Pharmaceuticals | Kisqali | $115 | 2 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $103 | 4 payments
|
| Coherus Biosciences | Udenyca | $101 | 3 payments
|
| Eisai | Lenvima | $100 | 5 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $96 | 5 payments
|
| Ipsen Biopharmaceuticals | Somatuline Depot | $90 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $73 | 3 payments
|
| Astellas Pharma US | Xtandi | $71 | 3 payments
|
| Puma Biotechnology | Nerlynx | $54 | 3 payments
|
| Alexion Pharmaceuticals | Ultomiris | $51 | 3 payments
|
| Gilead Sciences | Trodelvy | $49 | 3 payments
|
| Myovant Sciences | Orgovyx | $39 | 2 payments
|
| Rigel Pharmaceuticals | Tavalisse | $39 | 2 payments
|
| TOLMAR Pharmaceuticals | Eligard | $36 | 2 payments
|
| BeiGene USA | Brukinsa | $31 | 2 payments
|
| Taiho Oncology | Inqovi | $24 | 1 payment
|
| Regeneron Healthcare Solutions | Libtayo | $24 | 1 payment
|
| Deciphera Pharmaceuticals | Qinlock | $22 | 1 payment
|
| Foundation Medicine | Foundationone | $22 | 1 payment
|
| Daiichi Sankyo | Injectafer | $20 | 1 payment
|
| Jazz Pharmaceuticals | Zepzelca | $20 | 1 payment
|
| Tg Therapeutics | Ukoniq | $19 | 1 payment
|
| EMD Serono | None | $17 | 1 payment
|
| Aveo Pharmaceuticals | Fotivda | $16 | 1 payment
|
| MorphoSys US | Monjuvi | $16 | 1 payment
|
| Heron Therapeutics | Sustol | $15 | 1 payment
|
| Array Biopharma | Braftovi | $14 | 1 payment
|
| Ge Healthcare | None | $12 | 1 payment
|
2020: $4,853
| Novartis Pharmaceuticals | Kisqali | $638 | 13 payments
|
| Karyopharm Therapeutics | Xpovio | $330 | 10 payments
|
| Pfizer | Ibrance | $306 | 19 payments
|
| Seagen | Adcetris | $297 | 16 payments
|
| Incyte | Jakafi | $291 | 13 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $277 | 16 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $243 | 13 payments
|
| Merck Sharp & Dohme | Keytruda | $192 | 9 payments
|
| GlaxoSmithKline | Zejula | $179 | 6 payments
|
| Genzyme | Sarclisa | $152 | 8 payments
|
| Bayer HealthCare Pharmaceuticals | Stivarga | $133 | 8 payments
|
| Puma Biotechnology | Nerlynx | $124 | 5 payments
|
| Takeda Pharmaceuticals U.S.A. | None | $119 | 4 payments
|
| Teva Pharmaceuticals USA | Bendeka | $113 | 5 payments
|
| Ipsen Biopharmaceuticals | Somatuline Depot | $106 | 3 payments
|
| Celgene | Inrebic | $100 | 4 payments
|
| Lilly USA | Alimta | $99 | 5 payments
|
| Eisai | Lenvima | $95 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $87 | 4 payments
|
| Genentech USA | Tecentriq | $83 | 4 payments
|
| Blueprint Medicines | Gavreto | $79 | 4 payments
|
| TOLMAR Pharmaceuticals | Eligard | $78 | 4 payments
|
| Alexion Pharmaceuticals | Ultomiris | $77 | 4 payments
|
| Amgen | Nplate | $77 | 3 payments
|
| Astellas Pharma US | Xtandi | $69 | 3 payments
|
| Daiichi Sankyo | Injectafer | $65 | 3 payments
|
| Clovis Oncology | Rubraca | $55 | 3 payments
|
| Verastem | Copiktra | $49 | 2 payments
|
| Rigel Pharmaceuticals | Tavalisse | $48 | 2 payments
|
| Foundation Medicine | Foundationone | $47 | 2 payments
|
| Epizyme | Tazverik | $37 | 2 payments
|
| TerSera Therapeutics | Zoladex | $36 | 1 payment
|
| AbbVie | Venclexta | $32 | 2 payments
|
| Coherus Biosciences | Udenyca | $25 | 1 payment
|
| Jazz Pharmaceuticals | Zepzelca | $24 | 1 payment
|
| Taiho Oncology | Lonsurf | $24 | 1 payment
|
| Exelixis | Cabometyx | $22 | 1 payment
|
| Mylan Institutional | Ogivri | $18 | 1 payment
|
| Regeneron Healthcare Solutions | Libtayo | $17 | 1 payment
|
| BeiGene USA | Brukinsa | $11 | 1 payment
|
2019: $5,102
| Novartis Pharmaceuticals | Kisqali | $855 | 21 payments
|
| Genentech USA | Tecentriq | $495 | 22 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $307 | 23 payments
|
| Merck Sharp & Dohme | Keytruda | $262 | 15 payments
|
| Pfizer | Xtandi | $232 | 23 payments
|
| Janssen Biotech | Darzalex | $207 | 7 payments
|
| Bayer HealthCare Pharmaceuticals | Stivarga | $196 | 5 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $191 | 7 payments
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $191 | 10 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $179 | 11 payments
|
| Exelixis | Cabometyx | $159 | 7 payments
|
| Tesaro | Zejula | $152 | 10 payments
|
| Genzyme | Elitek | $150 | 8 payments
|
| Agios Pharmaceuticals | Tibsovo | $135 | 2 payments
|
| Celgene | Revlimid | $118 | 6 payments
|
| Amgen | Neulasta | $116 | 5 payments
|
| Lilly USA | Erbitux | $114 | 6 payments
|
| Puma Biotechnology | Nerlynx | $105 | 5 payments
|
| Incyte | Jakafi | $105 | 5 payments
|
| Teva Pharmaceuticals USA | Bendeka | $90 | 5 payments
|
| EMD Serono | Bavencio | $90 | 4 payments
|
| Seattle Genetics | Adcetris | $80 | 5 payments
|
| Alexion Pharmaceuticals | Ultomiris | $74 | 4 payments
|
| Astellas Pharma US | Xtandi | $73 | 3 payments
|
| Ipsen Biopharmaceuticals | Somatuline Depot | $67 | 3 payments
|
| Rigel Pharmaceuticals | Tavalisse | $66 | 3 payments
|
| Daiichi Sankyo | Injectafer | $47 | 2 payments
|
| Eisai | Lenvima | $40 | 2 payments
|
| Verastem | Copiktra | $39 | 2 payments
|
| GlaxoSmithKline | Zejula | $34 | 1 payment
|
| Taiho Oncology | Lonsurf | $25 | 1 payment
|
| Clovis Oncology | Rubraca | $25 | 2 payments
|
| Regeneron Healthcare Solutions | Libtayo | $24 | 1 payment
|
| Dova Pharmaceuticals | Doptelet | $23 | 1 payment
|
| TerSera Therapeutics | Zoladex | $17 | 1 payment
|
| Helsinn Therapeutics (U.S.) | Akynzeo | $12 | 1 payment
|
| Janssen Pharmaceuticals | Erleada | $9 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| E.R. Squibb & Sons, L.L.C. · A Phase Iiib/IV Safety Trial of Nivolumab (Bms-936558) in Subjects With Advanced Or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During Or After Receiving at Least One Prior Systemic Regimen · 2022 | Their institution | $3,750 |
| Spectrum Pharmaceuticals Inc. · Spi-Poz-101 · 2019 | Their institution | $1,858 |
Checkups this office reported
9 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Advance care plan on fileOlder patients with an advance care plan or a documented conversation about one | 88%That's most of the people this applied to. | 772 |
| Appropriate Treatment for Patients with Stage I (T1c) - III HER2 Positive Breast CancerAs Medicare defines this measure | 100% | 74 |
| Asked about smokingPatients asked about tobacco, with help to quit if they smoke | 90%That's most of the people this applied to. | 100 |
| Breast cancer screeningEligible women who got a mammogram | 0%That's few of the people this applied to. | 892 |
| Colon cancer screeningEligible adults who got a colon cancer test | 1%That's few of the people this applied to. | 1,364 |
| Depression screeningPatients screened for depression, with a follow-up plan if needed | 79%That's most of the people this applied to. | 1,882 |
| Medications listed in the chartVisits where the current medication list was documented | 67%That's more than half. | 7,987 |
| Oncology: Medical and Radiation - Pain Intensity QuantifiedAs Medicare defines this measure | 80% | 2,140 |
See the other 1 measures
| Oncology: Medical and Radiation - Plan of Care for PainAs Medicare defines this measure | 37% | 38 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Provide 24/7 Access to MIPS Eligible Clinicians or Groups Who Have Real-Time Access to Patient's Medical Record
Professional record
- NPI
- 1508885088
- Licence
- CA A88517California A88517: Current · expires 2028-07-31
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A885170
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 541 W Colorado St Ste 205, Glendale, CA, 91204
- NPI first listed
- 2006-07-18
- NPI last updated
- 2021-09-14
- NPI record certified
- 2021-09-14
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 3808 W Riverside Dr, Burbank, CA, 91505 · 222 W Eulalia St Ste 100c, Glendale, CA, 91204